Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride can cause enlarged breasts.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

This meta-analysis found that spironolactone use was linked to a decreased risk of prostate cancer but not to a significant risk increase for several other cancers, although the evidence certainty was low.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This study reported that newly synthesized progesterone derivatives significantly reduced prostate weight in testosterone-treated hamsters, with 5alpha-reductase inhibitory activity dependent on the size of the substituent at C-17.

Young and adult hamsters both respond similarly to testosterone and finasteride treatments, but young hamsters aren't good for testing the inhibitory activity of a specific enzyme.

This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.

This review discusses the natural progression of androgenetic alopecia and potential factors influencing its long-term prognosis, reporting no new clinical results.

Dutasteride reduces DHT more effectively than finasteride.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This review discusses differences in ERβ signaling between rodents and humans and reports no new clinical results; the authors highlight the need for further research in humans before using ERβ agonists clinically.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

This review evaluates existing preclinical and clinical studies on stromal vascular fraction for treating male sexual dysfunction, finding limited data and emphasizing the need for more research before conducting clinical trials.

This review examines reports of prolonged sexual dysfunction and depression associated with finasteride for male pattern hair loss, concluding that significant biases exist and further rigorous trials are needed to assess risks.

This case study reports a 66-year-old woman developing shortness of breath while taking 50 mg/day of cyproterone acetate for androgenetic alopecia, a complication not previously documented in women with this condition.

This study reported that patients with alopecia areata or alopecia totalis/universalis have a slightly increased overall cancer risk compared to controls, with specific increases in thyroid, bladder, and prostate cancers depending on the alopecia type.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This review suggests that telocytes in male reproductive organs help organize tissue structure and paracrine factors, impacting organ development and pathology, but more research is needed on their molecular pathways.

This article reviews the safety of finasteride by examining existing literature and does not report new findings, highlighting the ongoing controversies regarding its adverse effects.

In this study, D-004 did not affect androgen-dependent development in rats exposed in utero, while finasteride caused significant changes in male offspring's androgen-dependent tissues.

In this study, the safety of finasteride in rats varied depending on dosing time, while its effectiveness on prostate weight reduction remained consistent.

This research found that Leydig cells significantly rely on synthesizing omega-6 HUFAs to support male steroid hormone production, highlighting a new role for these fatty acids in the male reproductive system.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

This study found that certain male pattern baldness subtypes at age 45 are associated with an increased risk of developing colorectal neoplasia.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

In this study, five-year testosterone replacement therapy improved fasting blood sugar, HbA1c, and triglyceride levels in Japanese hypogonadal men without significantly affecting prostate-specific antigen levels.

This study found that the risk of urinary stone disease increased significantly in patients with severe androgenetic alopecia, and that testosterone deficiency was more frequent among these patients.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.